JP2021527087A5 - - Google Patents
Info
- Publication number
- JP2021527087A5 JP2021527087A5 JP2020568984A JP2020568984A JP2021527087A5 JP 2021527087 A5 JP2021527087 A5 JP 2021527087A5 JP 2020568984 A JP2020568984 A JP 2020568984A JP 2020568984 A JP2020568984 A JP 2020568984A JP 2021527087 A5 JP2021527087 A5 JP 2021527087A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- microrna
- promoter
- mir145
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684774P | 2018-06-14 | 2018-06-14 | |
| US62/684,774 | 2018-06-14 | ||
| PCT/US2019/037174 WO2019241624A1 (en) | 2018-06-14 | 2019-06-14 | Use of mir-92a or mir-145 in the treatment of angelman syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527087A JP2021527087A (ja) | 2021-10-11 |
| JP2021527087A5 true JP2021527087A5 (https=) | 2022-06-10 |
| JPWO2019241624A5 JPWO2019241624A5 (https=) | 2022-06-10 |
Family
ID=68839583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568984A Withdrawn JP2021527087A (ja) | 2018-06-14 | 2019-06-14 | アンジェルマン症候群の処置におけるＭＩＲ−９２ａまたはＭＩＲ−１４５の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10704048B2 (https=) |
| EP (1) | EP3793567A4 (https=) |
| JP (1) | JP2021527087A (https=) |
| KR (1) | KR20210040358A (https=) |
| CN (1) | CN112739353A (https=) |
| AU (1) | AU2019285298A1 (https=) |
| CA (1) | CA3103267A1 (https=) |
| IL (1) | IL279391A (https=) |
| MX (1) | MX2020013667A (https=) |
| WO (1) | WO2019241624A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002148A (es) * | 2017-08-25 | 2020-07-20 | Ovid Therapeutics Inc | Vectores adenoasociados recombinantes. |
| MX2020013667A (es) | 2018-06-14 | 2021-03-02 | Ovid Therapeutics Inc | Uso de mir-92a o mir-145 en el tratamiento del sindrome de angelman. |
| WO2020227604A1 (en) * | 2019-05-08 | 2020-11-12 | Nova Southeastern University | Regulation of nucleotide excision repair (ner) by microrna for treatment of breast cancer |
| KR20230128001A (ko) * | 2020-12-01 | 2023-09-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 엔젤만 증후군의 치료를 위한 조성물 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5752515A (en) | 1996-08-21 | 1998-05-19 | Brigham & Women's Hospital | Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier |
| WO2006128245A1 (en) | 2005-06-03 | 2006-12-07 | Southern Adelaide Health Service-Flinders Medical Centre | Targeting cells with altered microrna expression |
| EP1937151A4 (en) | 2005-09-19 | 2011-07-06 | Univ Columbia | Systems and methods for opening of the blood-brain barrier of a subject using ultrasound |
| CN102676516B (zh) * | 2011-03-17 | 2014-06-04 | 中国医学科学院肿瘤研究所 | microRNA 145的新用途 |
| WO2013056216A1 (en) * | 2011-10-14 | 2013-04-18 | New York University | Micrornas and methods of using same |
| AU2013262709A1 (en) * | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| ES2809199T3 (es) | 2012-06-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | Modulación de la expresión de UBE3A-ATS |
| HUE062186T2 (hu) * | 2015-05-07 | 2023-09-28 | Univ South Florida | Módosított UBE3A gén az Angelman-szindróma génterápiás megközelítésére |
| US20190298843A1 (en) * | 2015-05-11 | 2019-10-03 | Purdue Research Foundation | Ligand ionophore conjugates |
| IL256912B2 (en) * | 2015-07-17 | 2024-01-01 | Ovid Therapeutics Inc | Methods of treating developmental disorders with gaboxadol |
| MX2020013667A (es) | 2018-06-14 | 2021-03-02 | Ovid Therapeutics Inc | Uso de mir-92a o mir-145 en el tratamiento del sindrome de angelman. |
-
2019
- 2019-06-14 MX MX2020013667A patent/MX2020013667A/es unknown
- 2019-06-14 WO PCT/US2019/037174 patent/WO2019241624A1/en not_active Ceased
- 2019-06-14 US US16/441,391 patent/US10704048B2/en active Active
- 2019-06-14 JP JP2020568984A patent/JP2021527087A/ja not_active Withdrawn
- 2019-06-14 EP EP19819943.2A patent/EP3793567A4/en not_active Withdrawn
- 2019-06-14 AU AU2019285298A patent/AU2019285298A1/en not_active Abandoned
- 2019-06-14 KR KR1020217001109A patent/KR20210040358A/ko not_active Withdrawn
- 2019-06-14 CA CA3103267A patent/CA3103267A1/en active Pending
- 2019-06-14 CN CN201980040006.2A patent/CN112739353A/zh active Pending
-
2020
- 2020-07-07 US US16/922,273 patent/US11130952B2/en active Active
- 2020-12-13 IL IL279391A patent/IL279391A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527087A5 (https=) | ||
| US10392632B2 (en) | AAV8 vector with enhanced functional activity and methods of use thereof | |
| JP2021512649A5 (https=) | ||
| US10413598B2 (en) | Factor IX gene therapy | |
| JP2020522269A5 (https=) | ||
| RU2020109343A (ru) | Полинуклеотиды aadc для лечения болезни паркинсона | |
| JP2021500049A (ja) | 神経変性疾患の遺伝子治療 | |
| JP2021511803A5 (https=) | ||
| IL299325B2 (en) | Acid-alpha glucosidase variants and uses thereof | |
| JP2022501060A5 (https=) | ||
| JP2021512072A5 (https=) | ||
| JP2020537542A (ja) | ライソゾーム病の遺伝子治療 | |
| KR20240090694A (ko) | 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 | |
| JPWO2020106916A5 (https=) | ||
| KR20210096168A (ko) | 신경퇴행성 질환을 위한 유전자 요법 | |
| JP2018533976A5 (https=) | ||
| JP2021531044A5 (https=) | ||
| JP2021533801A5 (https=) | ||
| CN114231532B (zh) | 在哺乳动物肌肉中特异性启动基因的启动子序列及其应用 | |
| JPWO2019153009A5 (https=) | ||
| JP2023500793A (ja) | アルツハイマー病に対する遺伝子治療方法 | |
| JP2020510433A5 (https=) | ||
| EP4149622A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
| JP2021505619A5 (https=) | ||
| JPWO2020069339A5 (https=) |